Cargando…
A meta-analysis: neoadjuvant chemotherapy versus primary surgery in ovarian carcinoma FIGO stageIII and IV
BACKGROUND: The purpose of the current study is to analyze the existing data comparing neoadjuvant chemotherapy with primary debulking surgery (PDS) in patients with advanced ovarian carcinoma. METHODS: Patients with stage IIIC and IV ovarian cancer were identified from articles in Medline, PubMed,...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3852916/ https://www.ncbi.nlm.nih.gov/pubmed/24112995 http://dx.doi.org/10.1186/1477-7819-11-267 |
_version_ | 1782478744565317632 |
---|---|
author | Dai-yuan, Ma Bang-xian, Tan Xian-fu, Li Ye-qin, Zhou Hong-Wei, Cai |
author_facet | Dai-yuan, Ma Bang-xian, Tan Xian-fu, Li Ye-qin, Zhou Hong-Wei, Cai |
author_sort | Dai-yuan, Ma |
collection | PubMed |
description | BACKGROUND: The purpose of the current study is to analyze the existing data comparing neoadjuvant chemotherapy with primary debulking surgery (PDS) in patients with advanced ovarian carcinoma. METHODS: Patients with stage IIIC and IV ovarian cancer were identified from articles in Medline, PubMed, Cochrane Library, and EMBASE database (1989 to February 2013). Two authors independently extracted the data. To assess the risk of bias of included literatures, Cochrane Collaboration’s risk of bias tool was used. Meta-analysis on literatures was conducted by using RevMan 5.2 software. RESULTS: Two high-quality randomized controlled trials (RCTs) met the inclusion criteria. These multicenter trials randomized 1,220 women with stage IIIc/IV ovarian cancer to NACT or PDS followed by chemotherapy. There were no significant differences between the study groups with regard to overall survival (OS) (1,120 women; HR 0.98; 95% CI 0.85 to 1.14) or progression-free survival (PFS) (1,120 women; HR 1.03; 95% CI 0.91 to 1.16). CONCLUSION: There was no statistical difference in median OS and PFS between the two treatment groups. With regard to selecting who will benefit from NACT, treatment should be tailored to the patient and should take into account respectability, age, histology, stage, and performance status. |
format | Online Article Text |
id | pubmed-3852916 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-38529162013-12-07 A meta-analysis: neoadjuvant chemotherapy versus primary surgery in ovarian carcinoma FIGO stageIII and IV Dai-yuan, Ma Bang-xian, Tan Xian-fu, Li Ye-qin, Zhou Hong-Wei, Cai World J Surg Oncol Review BACKGROUND: The purpose of the current study is to analyze the existing data comparing neoadjuvant chemotherapy with primary debulking surgery (PDS) in patients with advanced ovarian carcinoma. METHODS: Patients with stage IIIC and IV ovarian cancer were identified from articles in Medline, PubMed, Cochrane Library, and EMBASE database (1989 to February 2013). Two authors independently extracted the data. To assess the risk of bias of included literatures, Cochrane Collaboration’s risk of bias tool was used. Meta-analysis on literatures was conducted by using RevMan 5.2 software. RESULTS: Two high-quality randomized controlled trials (RCTs) met the inclusion criteria. These multicenter trials randomized 1,220 women with stage IIIc/IV ovarian cancer to NACT or PDS followed by chemotherapy. There were no significant differences between the study groups with regard to overall survival (OS) (1,120 women; HR 0.98; 95% CI 0.85 to 1.14) or progression-free survival (PFS) (1,120 women; HR 1.03; 95% CI 0.91 to 1.16). CONCLUSION: There was no statistical difference in median OS and PFS between the two treatment groups. With regard to selecting who will benefit from NACT, treatment should be tailored to the patient and should take into account respectability, age, histology, stage, and performance status. BioMed Central 2013-10-10 /pmc/articles/PMC3852916/ /pubmed/24112995 http://dx.doi.org/10.1186/1477-7819-11-267 Text en Copyright © 2013 Dai-yuan et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Dai-yuan, Ma Bang-xian, Tan Xian-fu, Li Ye-qin, Zhou Hong-Wei, Cai A meta-analysis: neoadjuvant chemotherapy versus primary surgery in ovarian carcinoma FIGO stageIII and IV |
title | A meta-analysis: neoadjuvant chemotherapy versus primary surgery in ovarian carcinoma FIGO stageIII and IV |
title_full | A meta-analysis: neoadjuvant chemotherapy versus primary surgery in ovarian carcinoma FIGO stageIII and IV |
title_fullStr | A meta-analysis: neoadjuvant chemotherapy versus primary surgery in ovarian carcinoma FIGO stageIII and IV |
title_full_unstemmed | A meta-analysis: neoadjuvant chemotherapy versus primary surgery in ovarian carcinoma FIGO stageIII and IV |
title_short | A meta-analysis: neoadjuvant chemotherapy versus primary surgery in ovarian carcinoma FIGO stageIII and IV |
title_sort | meta-analysis: neoadjuvant chemotherapy versus primary surgery in ovarian carcinoma figo stageiii and iv |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3852916/ https://www.ncbi.nlm.nih.gov/pubmed/24112995 http://dx.doi.org/10.1186/1477-7819-11-267 |
work_keys_str_mv | AT daiyuanma ametaanalysisneoadjuvantchemotherapyversusprimarysurgeryinovariancarcinomafigostageiiiandiv AT bangxiantan ametaanalysisneoadjuvantchemotherapyversusprimarysurgeryinovariancarcinomafigostageiiiandiv AT xianfuli ametaanalysisneoadjuvantchemotherapyversusprimarysurgeryinovariancarcinomafigostageiiiandiv AT yeqinzhou ametaanalysisneoadjuvantchemotherapyversusprimarysurgeryinovariancarcinomafigostageiiiandiv AT hongweicai ametaanalysisneoadjuvantchemotherapyversusprimarysurgeryinovariancarcinomafigostageiiiandiv AT daiyuanma metaanalysisneoadjuvantchemotherapyversusprimarysurgeryinovariancarcinomafigostageiiiandiv AT bangxiantan metaanalysisneoadjuvantchemotherapyversusprimarysurgeryinovariancarcinomafigostageiiiandiv AT xianfuli metaanalysisneoadjuvantchemotherapyversusprimarysurgeryinovariancarcinomafigostageiiiandiv AT yeqinzhou metaanalysisneoadjuvantchemotherapyversusprimarysurgeryinovariancarcinomafigostageiiiandiv AT hongweicai metaanalysisneoadjuvantchemotherapyversusprimarysurgeryinovariancarcinomafigostageiiiandiv |